| A 1.1-Mb transcript map of the hereditary hemochromatosis locus DA Ruddy, GS Kronmal, VK Lee, GA Mintier, L Quintana, R Domingo, ... Genome research 7 (5), 441-456, 1997 | 112 | 1997 |
| A chemical genetics approach for the functional assessment of novel cancer genes Q Zhou, A Derti, D Ruddy, D Rakiec, I Kao, M Lira, V Gibaja, HM Chan, ... Cancer research 75 (10), 1949-1958, 2015 | 131 | 2015 |
| A CRISPR screen reveals resistance mechanisms to CD3-bispecific antibody therapy SQ Liu, A Grantham, C Landry, B Granda, R Chopra, S Chakravarthy, ... Cancer immunology research 9 (1), 34-49, 2021 | 9 | 2021 |
| A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients R Tiedt, E Degenkolbe, P Furet, BA Appleton, S Wagner, J Schoepfer, ... Cancer research 71 (15), 5255-5264, 2011 | 129 | 2011 |
| A novel MHC class I-like gene is mutated in patients with hemochromatosis JN Feder, A Gnirke, W Thomas, Z Tsuchihashi, DA Ruddy, NJ Risch, ... Blood 88 (10), 2579-2579, 1996 | 4 | 1996 |
| A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis JN Feder, A Gnirke, W Thomas, Z Tsuchihashi, DA Ruddy, A Basava, ... Nature genetics 13 (4), 399-408, 1996 | 4678 | 1996 |
| A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts AC Palmer, D Plana, H Gao, JM Korn, G Yang, J Green, X Zhang, ... Cancer research 80 (19), 4278-4287, 2020 | 13 | 2020 |
| Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmut NSCLC JL Cotton, V KrishnamurthyRadhakrishna, J Chen, M Piquet, J Wagner, ... Molecular Cancer Therapeutics 18 (12_Supplement), A122-A122, 2019 | | 2019 |
| Abstract A142: Targeting FGFR to overcome EMT-related resistance in EGFR-mutated non-small cell lung cancer S Raoof, D Ruddy, D Timonia, L Damon, J Engelman, A Hata Molecular Cancer Therapeutics 17 (1_Supplement), A142-A142, 2018 | 1 | 2018 |
| Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC L Dardaei, HQ Wang, M Singh, P Fordjour, S Yoda, G Kerr, J Liang, Y Cao, ... Molecular Cancer Therapeutics 17 (1_Supplement), A145-A145, 2018 | | 2018 |
| Abstract A54: shRNA screens in cancer cells revealed cell-context dependent cross-talk between RAF-MEK-ERK pathway and DR5 mediated apoptosis J Zhang, J Li, Z Li, S Doshi, Y Chen, X Li, D Ruddy, P Fordjour, ... Clinical Cancer Research 16 (14_Supplement), A54-A54, 2010 | | 2010 |
| Abstract LB-017: disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5 K Mavrakis, ER McDonald III, MR Schlabach, E Billy, GR Hoffman, ... Cancer Research 76 (14_Supplement), LB-017-LB-017, 2016 | 1 | 2016 |
| Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance JL Cotton, VK Radhakrishna, JE Diez, DA Ruddy, K Sprouffske, G Boulay, ... Cancer Research 80 (21_Supplement), PO-100-PO-100, 2020 | | 2020 |
| An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) M Korpal, JM Korn, X Gao, DP Rakiec, DA Ruddy, S Doshi, J Yuan, ... Cancer discovery 3 (9), 1030-1043, 2013 | 608 | 2013 |
| aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation R Francis, G McGrath, J Zhang, DA Ruddy, M Sym, J Apfeld, M Nicoll, ... Developmental cell 3 (1), 85-97, 2002 | 1187 | 2002 |
| Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts AC Palmer, D Plana, H Gao, JM Korn, G Yang, J Green, X Zhang, ... bioRxiv, 2020.01. 08.898734, 2020 | | 2020 |
| BRAF-inhibitor associated MEK mutations increase RAF-dependent and-independent enzymatic activity CM Emery, KA Monaco, P Wang, M Balak, A Freeman, J Meltzer, ... Molecular Cancer Research 15 (10), 1431-1444, 2017 | 26 | 2017 |
| Cellular resistance screening with a novel selective c-Met inhibitor reveals a spectrum of missense mutations that partially overlap with activating mutations found in cancer … R Tiedt, E Degenkolbe, P Furet, BA Appleton, J Schoepfer, D Ruddy, ... Cancer Research 71 (8_Supplement), 4738-4738, 2011 | | 2011 |
| Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models HQ Wang, E Halilovic, X Li, J Liang, Y Cao, DP Rakiec, DA Ruddy, S Jeay, ... Elife 6, e17137, 2017 | 56 | 2017 |
| Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer EB Krall, B Wang, DM Munoz, N Ilic, S Raghavan, MJ Niederst, K Yu, ... Elife 6, e33173, 2017 | 5 | 2017 |
